Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 480
Summary
- Conditions
- Human
- Influenza
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 50 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04576702
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Program Director Seqirus